X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Press Statements

OliX Pharma Announces Expansion of Collaboration with Laboratoires Thea to Develop siRNA Therapeutics for Ophthalmic Diseases

Content Team by Content Team
12th October 2020
in Press Statements
OliX Pharma Announces Expansion of Collaboration with Laboratoires Thea to Develop siRNA Therapeutics for Ophthalmic Diseases

OliX Pharmaceuticals, Inc., a leading developer of RNAi therapeutics, announced a collaboration with Théa Open Innovation, a sister company of Laboratoires Théa S.A.S (“Théa”), the leading independent pharmaceutical company in Europe dedicated to ophthalmology, to develop OliX’ lead pipeline products OLX301A and OLX301D in Age-related Macular Degeneration (AMD) and subretinal fibrosis along two other ophthalmic pipelines upon exercise of the option. As a part of the collaborative agreement, Théa will have worldwide rights excluding Asia-Pacific for four programs.

Théa will pay OliX an additional upfront payment of €8.8 million, as well as development and commercialization milestones depending on the progression of the two AMD programs and the triggering of the option. This licensing deal is a continuation of an earlier licensing agreement between the two Companies in 2019, where Théa gained rights to OLX301A program in the EU, Middle East and Africa.

“Having begun our work with Théa in 2019, we are pleased to continue and expand this successful collaboration,” said Dong Ki Lee, Ph.D., founder and Chief Executive Officer of OliX Pharmaceuticals. “We look forward to working side by side with Théa to leverage our proprietary asiRNA platform, utilizing OLX301A and OLX301D to bring our ophthalmic RNAi programs to the clinic. We are also excited at the prospect of collaborating on additional pipeline products for ophthalmic diseases.”

OLX301A is OliX Pharmaceuticals’ first-in-class therapeutic that targets both wet AMD and dry AMD. OLX301D is also first-in-class therapeutic currently in development for both wet AMD and subretinal fibrosis. Both utilize OliX’ proprietary and novel siRNA therapeutic platform to target diseased tissue.

“We are thrilled to partner with OliX Pharmaceuticals and look forward to utilizing our complementary capabilities in ophthalmology to make an impact in AMD and other eye diseases across the world,” said Jean-Frédéric Chibret, President of Laboratoires Théa. “We’ve had a very successful collaboration for more than a year and are impressed with the speed and agility of OliX Pharmaceuticals’ work in developing novel siRNA therapeutics to target diseased tissues. Together, we are committed to advancing RNAi therapy to provide clinical solutions to diseases of the eye. This extension of our current agreement is in line with our commitment to enter in the field of retina, and to build a strong pipeline for the European and US market.

Asymmetric small interfering RNA

Asymmetric small interfering RNA (asiRNA) is the next generation of RNAi therapeutics that offers efficient gene regulation. In comparison to existing siRNA therapeutics, OliX Pharmaceutical’s asiRNA shows comparable gene silencing and significantly reduce siRNA-mediated side effects such as off-target gene silencing and immune stimulation.

OliX Pharmaceuticals

OliX Pharmaceuticals is a clinical stage pharmaceutical company developing therapeutics against a variety of disorders by down-regulating expression of disease-causing genes, based on its own proprietary RNAi technology. The Company’s core RNAi platform, asymmetric siRNA (asiRNA), is a unique gene silencing technology based on RNA interference (RNAi), which is considered as the most efficient gene silencing technology. Based on asiRNA technology, OliX has developed cell penetrating asiRNA (cp-asiRNA), a therapeutic RNAi platform to effectively target locally administrable diseases, such as hypertrophic scar, dry and wet age-related macular degeneration (AMD), subretinal fibrosis, idiopathic pulmonary fibrosis (IPF), and neuropathic pain. OliX has also developed another therapeutic RNAi platform, GalNAc-asiRNA, to target a variety of liver diseases.

Previous Post

Amgen Announces Positive Topline Phase 2 Results For Investigational KRAS G12C Inhibitor Sotorasib In Lung Cancer

Next Post

Worldwide Flight Services prepares for Covid-19 vaccine with Project Coldstream

Related Posts

Pharmapack 2023 a pivotal moment for sustainability in drug delivery and packaging
Europe

Pharmapack 2023 a pivotal moment for sustainability in drug delivery and packaging

3rd March 2023
Canada's National Carrier Air Canada Cargo and the Cool Tech Company ColdChase join Pharma.Aero
Manufacturing

Canada’s National Carrier Air Canada Cargo and the Cool Tech Company ColdChase join Pharma.Aero

22nd February 2023
Amyris and Immunitybio Complete Joint Venture for Next Generation Covid-19 RNA Vaccine
Drug Development

Clover Launches COVID-19 Booster Vaccine in the People’s Republic of China

21st February 2023
Labcorp Unveils New Name for Future Independent Clinical Development Business - Fortrea
Clinical Trials

Labcorp Unveils New Name for Future Independent Clinical Development Business – Fortrea

21st February 2023
Agilent Announces New NovoCyte Flow Cytometer System Software for 21 CFR Part 11 Compliance
IPR Data Management

Agilent Announces New NovoCyte Flow Cytometer System Software for 21 CFR Part 11 Compliance

21st February 2023
West Expands Corning Collaboration and Launches First Product
Packaging & Logistic

West Expands Corning Collaboration and Launches First Product

21st February 2023
Next Post
Worldwide Flight Services prepares for Covid-19 vaccine with Project Coldstream

Worldwide Flight Services prepares for Covid-19 vaccine with Project Coldstream

Latest News

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In